INTRODUCTION
Staphylococcus aureus and particularly meticillin-resistant S. aureus (MRSA) have become a major problem in hospital-acquired infections worldwide. Recently the World Health Organization recognized that antibiotic resistance is one of the major threats facing the world in the future (WHO, 2000) . Diseases of concern include AIDS, tuberculosis, malaria and hospital-acquired infections, including vancomycin-resistant enterococci and MRSA (WHO, 2000) . Between 1991 and 2000 the Health Protection Agency reported that bacteraemia cases caused by MRSA in the UK rose from 2 to 40 % (HPA, 2000) .
The typing of MRSA beyond the species level has become an important tool in aiding the identification and control of disease outbreaks, and monitoring the spread of different strains of MRSA, both nationally and internationally . There are a number of different genotyping methods utilized for the characterization of MRSA; however, PFGE is currently accepted as the 'gold standard' method due to the high degree of reproducibility and the excellent discriminatory power this method provides (Witte, 2000) .
Malta and the UK are included in the top five European countries showing high levels of MRSA infection (EARSS, 2007) . The aim of this study was to genetically type and compare MRSA isolate populations within the Maltese and UK clinical setting. This is believed to be the first report of strain profile comparisons between these two geographically separated locations.
period (07/2002-12/2004) . A total of 216 isolates were collected from St Luke's Hospital Malta, over an 8 month period (02/2003-10/2003) . Duplicate isolates from patient samples were excluded from the study.
Antibiotic-sensitivity testing. A panel of 14 different antibiotics were used for testing, 13 using standard operating procedures as defined by the British Society for Antimicrobial Chemotherapy (BSAC, 2004) . The antibiotics selected as determined by BSAC methodology were: amikacin, chloramphenicol, ciprofloxacin, clarithromycin, clindamycin, erythromycin, gentamicin, linezolid, meticillin, penicillin G, rifampicin, teicoplanin and tetracycline (MAST Diagnostic). In addition, sensitivity to vancomycin (Sigma) was assayed using a well established methodology described by Hubert et al. (1999) . The following S. aureus strains were used as controls: MRSA NCTC 12493 (control 1) and Oxford S. aureus NCTC 06571 (control 2).
PFGE. PFGE was performed as previously described by Bannerman et al. (1995) with modifications taken from the HARMONY protocol (Murchan et al., 2003) . Electrophoresis was carried out using a CHEF-DR II system (Bio-Rad) using a standard 23 h two block run method as detailed in the HARMONY protocol (Murchan et al., 2003) .
The gels were stained with ethidium bromide (BDH) as described by Murchan et al. (2003) . Band patterns were loaded into the Bionumerics [Jaccard (Tol 2.7-2.7)(H70.0 % s .0.0 %) (0.0 %-100.05)] analysis program producing a dendrogram. Banding patterns were interpreted using the criteria devised by Tenover et al. (1995) .
RESULTS AND DISCUSSION
The aim of this study was to type MRSA isolates collected from the two European study groups (LBH and Maltese hospital), by PFGE using SmaI. Antibiotic susceptibility testing demonstrated that all isolates retrieved from this study were susceptible to linezolid, teicoplanin and vancomycin (data not shown). All MRSA isolates were resistant to between 2 and 10 antibiotics (out of a panel of 14), with a mean resistance to 6 antimicrobials (data not shown). Multiple antibiotic resistance (MAR) profiles were generated for each isolate, the most predominant MAR profiles from both countries can be seen in Table 1 , which also includes the strain type to which these isolates belonged to (the predominant strain types are shown in bold). The MAR profiles accounted for 66 % (170/256) of the isolates from the LBH and 48 % (104/216) of the isolates from the Maltese hospital, with the remaining isolates falling into other MAR profiles containing less than 5 % of isolates within a given profile. The most common MAR profiles show resistance to six antibiotics (ciprofloxacin, clarithromycin, clindamycin, erythromycin, meticillin and penicillin G).
Of the 473 isolates tested, PFGE banding patterns were determined for 90.5 % (428/473) of isolates. Profiles were determined for 91.4 % (235/257) of LBH isolates and 89.4 % (193/216) of Maltese hospital isolates. A dendrogram ( Fig. 1 ) was constructed using these banding patterns and a total of 32 different PFGE profile groups were identified, with a varying number of subtypes within each group. PFGE profile groups were determined using three criteria: the guidelines formulated by Tenover et al. (1995) , the similarity (in the number and size of bands) to published banding patterns and the demographic similarity (60 % or greater) within a group of related isolates (Murchan et al., 2003) .
Of the 32 identified PFGE profile groups, 11 were found to be present in both the LBH and Maltese hospital cohorts (groups A-K) (Table 2) , of which approximately 90 % of the isolates (91 % LBH and 89 % Maltese hospital) tested from both cohorts were grouped into one of these profiles. The remaining 10 % of isolates from each cohort were found to belong to one of 21 unique profiles, which contained between one and five isolates only.
Two PFGE profile groups (D and E) were identified as being similar to published banding patterns for epidemic MRSA (EMRSA) clones. Approximately 60 % of isolates from both cohorts belonged to PFGE profile group E, which was determined to be closely related to the published banding pattern of EMRSA 15 (Murchan et al., 2003) . PFGE profile group E contained a main group and 37 subtypes, these subtypes varied from the main group by either insertion or deletion compared to the main banding pattern. The subtypes contained between 2 or 3 and 38 isolates.
Profile group D was determined to be closely related to the published banding pattern of EMRSA 16 (Murchan et al., 2003) . The majority of the isolates within profile group D were from LBH MRSA (14.3 %), and only a small percentage was from the Maltese hospital cohort (2.1 %). This profile group contained a main group and 13 subtypes. Conversely, profile group K contained predominantly Maltese hospital isolates (14.4 %); however, one isolate (0.4 %) was from the LBH cohort and was grouped into a subtype of this profile. Profile group K contained a main banding pattern and 13 subtypes. Additionally, this profile was not comparable to any currently published banding patterns. It is therefore tempting to speculate that this isolate might be a local Maltese strain. However, the observation was not confirmed in this study and more work on this specific point is required.
Of the remaining seven PFGE profiles groups that were identified in both countries, each contained between 0.4 and 4.8 % of the isolate population. These profiles were not found to be similar to known banding profiles for EMRSA isolates and varied in the number of subtypes that they contained.
Twenty-one PFGE profiles unique to a single cohort were identified (U1-U21). The LBH cohort was found to have 13 unique profiles, whereas the Maltese hospital group contained 9 unique profiles. Approximately 10 % of isolates from the LBH and Maltese hospital groups produced unique banding patterns.
Comparison of MAR profiles and PFGE profiles showed some clustering, strain type E, which has a similar banding pattern to EMRSA 15, was the predominant strain type for isolates that showed the most common MAR profile containing resistances to penicillin G, meticillin, clinda- mycin, erythromycin, clarithromycin and ciprofloxacin (Table 1 ). The second most common MAR profile contained the same resistances as listed previously, with the addition of gentamicin, and again the predominant strain type in this group was type E.
In the LBH cohort strain type D (which has a similar banding pattern to EMRSA 16) demonstrated a slightly different MAR profile. The basic profile contained seven antibiotics (amikacin, ciprofloxacin, clarithromycin, clindamycin, erythromycin, meticillin and penicillin G) and two different profiles contained the above antibiotics with the addition of either gentamicin or chloramphenicol. spread from Germany to the Czech Republic as these two countries share a border. Although the spread of the clones may be explained by increased travel, why these clones should have become established and then become the predominant clone in a few years is hard to explain. Antibiotic resistance evidence from both Montesinos et al. (2006) and Amorim et al. (2007) demonstrated that the EMRSA clones are more sensitive to antibiotics such as gentamicin and tetracycline than the Iberian or Brazilian clone. However, similar resistance levels to antibiotics such as ciprofloxacin, clindamycin, erythromycin and rifampicin were shown by all clones. It could therefore be speculated that both EMRSA 15 and 16 may be more pathogenic than the other clones, with a possible increased ability to adhere and proliferate within a wound or survive within this particular environment. However, further research would need to be carried out to support this suggestion. What is clear from this current study and other work is that EMRSA 15 and 16 appear to be spreading across a number of European countries, and that once established appear to rise to become the predominant clone.
